NCT00102063

Aripiprazole in Adolescents With Schizophrenia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 302 (actual)
• Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
• Sex: All
• Age: 13 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to test the safety and efficacy of aripiprazole in adolescent patients with schizophrenia for a period of at least 6 weeks.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Aripiprazole tablet, 10 mg	Aripiprazole tablet 10 mg po qd x 42 days
DRUG	Aripiprazole tablet, 30 mg	Aripiprazole tablet 30 mg po qd x 42 days
DRUG	Placebo tablet	Placebo tablet po qd x 42 days

Timeline

• Start date: 2004-07-01
• Primary completion: 2006-08-01
• Completion: 2006-08-01
• First posted: 2005-01-20
• Last updated: 2012-08-10
• Results posted: 2012-08-01

Locations

55 sites across 2 countries: United States, Puerto Rico